gonorrhea vaccine MenB cross protection
Selected indexed studies
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis. (J Infect Dis, 2025) [PMID:39082700]
- 4CMenB journey to the 10-year anniversary and beyond. (Hum Vaccin Immunother, 2024) [PMID:38976659]
- Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis. (Vaccine, 2025) [PMID:40339484]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- 4CMenB journey to the 10-year anniversary and beyond. (2024) pubmed
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis. (2025) pubmed
- Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis. (2025) pubmed
- Vaccine value profile for Neisseria gonorrhoeae. (2024) pubmed
- Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection. (2025) pubmed
- Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease. (2019) pubmed
- 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. (2023) pubmed
- Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. (2019) pubmed
- Infection With the US Neisseria meningitidis Urethritis Clade Does Not Lower Future Risk of Urethral Gonorrhea. (2022) pubmed
- Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol. (2024) pubmed